2016, Number 5
<< Back Next >>
Rev Med Inst Mex Seguro Soc 2016; 54 (5)
Frequency of invasive fungal infections in a Mexican High-Specialty Hospital. Experience of 21 years
Méndez-Tovar LJ, Mejía-Mercado JA, Manzano-Gayosso P, Hernández-Hernández F, López-Martínez R, Silva GI
Language: Spanish
References: 24
Page: 581-587
PDF size: 341.10 Kb.
ABSTRACT
Factors such as cancer, HIV infection, use of corticosteroids
and antibiotics, favors the increase in the number of invasive
fungal infections (IFI) worldwide. To determine the frequency
and epidemiological aspects of IFI at a mexican, a review of the
proven cases diagnosed over the past 21 years (1993-2013) in
the Laboratory of Medical Mycology was performed.
A total of 472 cases were identified as: 261 candidiasis, 82
mucormycosis, 60 cryptococcosis, 43 aspergillosis and 16 histoplasmosis.
A decrease in the frequency of candidiasis was
observed, with 74 cases in the first 6 years and 48 in the last
five.
C. albicans was the most common agent and pulmonary
infection the most prevalent. Cryptococcosis also declined from
24 to 10 cases, mainly caused by
C. neoformans; two cases
of
C. laurentii and
C. terreus and
C unigutulatus were isolated
once. Mucormycosis remained steady, but aspergillosis
increased significantly, and from 2 cases found in the first studied
period, it rose to 23 in the last one.
It is important that High Specialty Hospitals have well-equipped
laboratories of Medical Mycology. We suggest the creation of a
National Reference Center for Mycoses to collect all the data of
these infections, in order to help to the development of strategies
for health education, prevention, diagnosis and treatment
of them.
REFERENCES
Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34 (1):7-14.
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46(12):1813-21.
Pemán J, Salavert M. Epidemiología general de la enfermedad fúngica invasora. Enferm Infecc Microbiol Clin 2012;30(2):90-8.
Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36(1):1-53.
Paramythiotou E, Frantzeskaki F, Flevari A, et al. Invasive fungal infections in the ICU: how to approach, how to treat. Molecules 2014;19(1):1085-119.
Badiee P, Hashemizadeh Z. Opportunistic invasive fungal infections: diagnosis & clinical management. Indian J Med Res 2014;139(2):195-204.
Méndez-Tovar LJ, Manzano-Gayosso P, Cumplido- Uribe Ch, Hernández-Hernández F, Ramos-Hernández J, López-Martínez R. Micosis invasivas en pacientes inmunodeprimidos con fiebre de origen desconocido. Rev Med Inst Mex Seguro Soc 2012; 50(6):609-614.
Eggimann P, Bille J, Marchetti O. Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care 2011;1:37.
Gómez BL. Molecular diagnosis of endemic and invasive mycoses: advances and challenges. Rev Iberoam Micol 2014;31(1):35-41.
Álvez F, Figueras C, Roselló E. Infecciones fúngicas invasivas emergentes. Ann Pediatr (Barc) 2010;73 (1):52.e1-e6.
Miceli MH, Díaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis 2011;11(2):142-151.
Cruz R, Piontelli E. Enfermedad fúngica invasora en pacientes de cinco hospitales de la Región de Valparaíso, Chile. 2004 a 2009. Rev Chil Infect 2011;28 (2):123-129.
Montagna MT, Caggiano G, Lovero G, De Giglio O, Coretti C, Cuna T, et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection 2013;41(3):645-653.
Sifuentes-Osornio J, Corzo-León DE, Ponce-de- León LA. Epidemiology of Invasive Fungal Infections in Latin America. Curr Fungal Infect Rep 2012; 6(1):23-34.
Bitar D, Lortholary O, Le Strat Y, Nicolau J, Coignard B, Tattevin P, et al. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis 2014;20(7):1149-1155.
Quindós G, Eraso E, López-Soria LM, Ezpelata G. Enfermedad fúngica invasora: ¿Diagnóstico micológico convencional o molecular? Enferm Infecc Microbiol Clin 2012;30(9):560-571.
Ding X, Yan D, Sun W, Zeng Z, Su R, Su J. Epidemiology and risk factors for nosocomial Non-Candida albicans candidemia in adult patients at a tertiary care hospital in North China. Med Mycol 2015 Jul 30 (Epub ahead of print).
Hitchcock CA, Pye GW, Troke PF, Johnson EM, Warnock DW. Fluconazole resistance in Candida glabrata. Antimicrob Agent Chemother 1993;37(9): 1962-1965.
Loeffler J, Stevens DA. Antifungal drug resistance. Clin Infect Dis 2003;36 Suppl 1:S31-S41.
Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of mucormycosis: a review of 929 reported cases. Clin Infect Dis 2005;41(5):634-653.
Vehreschild JJ, Birtel A, Vehreschild MJ, Liss B, Farowski F, Kochanek M, et. al. Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol 2013;39(3):310-324.
Almannai M, Imran H, Estrada B, Siddiqui AH. Successful treatment of rhino-orbital mucormycosis with posaconazole and hyperbaric oxygen therapy. Pediatr Hematol Oncol 2013;30(3):184-186.
Narayan S, Batta K, Colloby P, Tan CY. Cutaneous cryptococcus infection due to C. albidus associated with Sézary syndrome. Br J Dermatol. 2000;143(3): 632-634.
Takemura H, Ohno H, Miura I, Takagi T, Ohyanagi T, Kunishima H, et. al. The first reported case of central venous catheter-related fungemia caused by Cryptococcus liquefaciens. J Infect Chemother. 2015;21 (5):392-394.
Full text